Pharming Group to Report Q4 and FY 2025 Results on March 12, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy PHAR?
Source: Newsfilter
- Earnings Report Announcement: Pharming Group has confirmed that it will release its preliminary (unaudited) financial results for Q4 and full year 2025 on March 12, 2026, aiming to communicate the latest financial status and strategic direction to investors and analysts.
- Conference Call Details: Management will host a conference call and webcast on the same day at 13:30 CET/08:30 am EDT, requiring participants to register in advance to obtain dial-in information and a unique PIN, thereby ensuring smooth proceedings and enhancing interaction with investors.
- Webcast Availability: The webcast will be accessible on Pharming's website under the Investors/Financial Documents section, with a replay available shortly after the event, ensuring that investors who cannot participate live can still access key information and enhancing transparency.
- Company Background: Pharming Group N.V. is a global biopharmaceutical company dedicated to developing and commercializing innovative medicines for rare, life-threatening diseases, supported by a professional team based in both the U.S. and the Netherlands, aiming to improve patient quality of life and drive long-term growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHAR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHAR
Wall Street analysts forecast PHAR stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.990
Low
37.00
Averages
39.50
High
42.00
Current: 15.990
Low
37.00
Averages
39.50
High
42.00
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Pharming Group N.V. regarding potential securities fraud by the company and its executives, which could lead to significant investor losses.
- FDA Response Letter: On February 1, 2026, Pharming announced that the FDA issued a Complete Response Letter for its Joenja® supplemental New Drug Application, requesting additional pediatric pharmacokinetic data to ensure safety for lower weight children.
- Significant Stock Drop: Following the FDA's announcement, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026, indicating market concerns about the company's future.
- Law Firm Background: Pomerantz LLP is a prominent firm in corporate and securities class litigation, established over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and has historically recovered multimillion-dollar damages for class members.
See More
Pharming Group to Report Q4 and FY 2025 Results on March 12, 2026
- Earnings Report Announcement: Pharming Group has confirmed that it will release its preliminary (unaudited) financial results for Q4 and full year 2025 on March 12, 2026, aiming to communicate the latest financial status and strategic direction to investors and analysts.
- Conference Call Details: Management will host a conference call and webcast on the same day at 13:30 CET/08:30 am EDT, requiring participants to register in advance to obtain dial-in information and a unique PIN, thereby ensuring smooth proceedings and enhancing interaction with investors.
- Webcast Availability: The webcast will be accessible on Pharming's website under the Investors/Financial Documents section, with a replay available shortly after the event, ensuring that investors who cannot participate live can still access key information and enhancing transparency.
- Company Background: Pharming Group N.V. is a global biopharmaceutical company dedicated to developing and commercializing innovative medicines for rare, life-threatening diseases, supported by a professional team based in both the U.S. and the Netherlands, aiming to improve patient quality of life and drive long-term growth.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. regarding potential securities fraud or other unlawful business practices, with investors encouraged to contact Danielle Peyton to join the class action.
- FDA Complete Response Letter: On February 1, 2026, Pharming received a Complete Response Letter from the FDA concerning its supplemental New Drug Application for Joenja®, highlighting concerns about potential underexposure in lower weight pediatric patients and requesting additional pharmacokinetic data.
- Significant Stock Drop: Following the FDA's announcement, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026, indicating market concerns regarding the company's future prospects.
- Law Firm Background: Pomerantz LLP is a premier law firm specializing in corporate, securities, and antitrust class litigation, founded over 85 years ago, and has a strong track record of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Pharming Group N.V. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and the company's reputation.
- FDA Response: On February 1, 2026, Pharming announced that the FDA issued a Complete Response Letter for its Joenja® supplemental New Drug Application, requesting additional pediatric pharmacokinetic data, potentially delaying product approval and impacting future revenues.
- Stock Price Decline: Following the FDA news, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 on February 2, 2026, reflecting market concerns about the company's outlook.
- Legal Implications: The investigation by Pomerantz LLP could lead to a class action lawsuit, and if fraud is confirmed, it may result in significant damages for Pharming, further affecting its financial health and market performance.
See More
Pharming Group to Present at Oppenheimer Healthcare Conference
- Conference Participation: Pharming Group will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with CEO Fabrice Chouraqui and CMO Anurag Relan presenting on February 25 at 12:40 PM ET, highlighting the company's advancements in rare disease treatments.
- Live Webcast: The presentation will be available via live webcast and replay on Pharming's website under the 'Upcoming Events' and 'News' sections, ensuring that investors and the public can access real-time information, thereby enhancing transparency.
- Investor Relations: Pharming encourages scheduling one-on-one meetings with its management team, allowing investors to connect directly through email, which strengthens investor engagement and improves the company's public image.
- Company Background: Pharming is a global biopharmaceutical company focused on developing and commercializing innovative medicines aimed at transforming the lives of patients with rare, life-threatening diseases, underscoring its strategic significance in the biopharmaceutical sector.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Pharming Group N.V. regarding potential securities fraud, focusing on whether the company and its executives engaged in unlawful business practices that could harm investors.
- FDA Response Letter: On February 1, 2026, Pharming received a Complete Response Letter from the FDA concerning its Joenja® supplemental New Drug Application, requesting additional pediatric pharmacokinetic data to ensure safety for lower weight children.
- Significant Stock Drop: Following the FDA's negative feedback, Pharming's American Depositary Receipt (ADR) fell by $3.495, or 17.07%, closing at $16.975 on February 2, 2026, indicating market concerns about the company's future prospects.
- Potential Legal Action: As the investigation unfolds, investors may face the risk of a class action lawsuit, with Pomerantz LLP providing contact information for affected investors to join potential legal proceedings for compensation.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Pharming Group N.V. regarding potential securities fraud by the company and its executives, which could lead to significant investor losses.
- FDA Response Letter: On February 1, 2026, Pharming announced that the FDA issued a Complete Response Letter for its Joenja® supplemental New Drug Application, requesting additional pediatric pharmacokinetic data to ensure safety for lower weight children.
- Significant Stock Drop: Following the FDA's announcement, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026, indicating market concerns about the company's future.
- Law Firm Background: Pomerantz LLP is a prominent firm in corporate and securities class litigation, established over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and has historically recovered multimillion-dollar damages for class members.
See More
Pharming Group to Report Q4 and FY 2025 Results on March 12, 2026
- Earnings Report Announcement: Pharming Group has confirmed that it will release its preliminary (unaudited) financial results for Q4 and full year 2025 on March 12, 2026, aiming to communicate the latest financial status and strategic direction to investors and analysts.
- Conference Call Details: Management will host a conference call and webcast on the same day at 13:30 CET/08:30 am EDT, requiring participants to register in advance to obtain dial-in information and a unique PIN, thereby ensuring smooth proceedings and enhancing interaction with investors.
- Webcast Availability: The webcast will be accessible on Pharming's website under the Investors/Financial Documents section, with a replay available shortly after the event, ensuring that investors who cannot participate live can still access key information and enhancing transparency.
- Company Background: Pharming Group N.V. is a global biopharmaceutical company dedicated to developing and commercializing innovative medicines for rare, life-threatening diseases, supported by a professional team based in both the U.S. and the Netherlands, aiming to improve patient quality of life and drive long-term growth.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. regarding potential securities fraud or other unlawful business practices, with investors encouraged to contact Danielle Peyton to join the class action.
- FDA Complete Response Letter: On February 1, 2026, Pharming received a Complete Response Letter from the FDA concerning its supplemental New Drug Application for Joenja®, highlighting concerns about potential underexposure in lower weight pediatric patients and requesting additional pharmacokinetic data.
- Significant Stock Drop: Following the FDA's announcement, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026, indicating market concerns regarding the company's future prospects.
- Law Firm Background: Pomerantz LLP is a premier law firm specializing in corporate, securities, and antitrust class litigation, founded over 85 years ago, and has a strong track record of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Pharming Group N.V. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and the company's reputation.
- FDA Response: On February 1, 2026, Pharming announced that the FDA issued a Complete Response Letter for its Joenja® supplemental New Drug Application, requesting additional pediatric pharmacokinetic data, potentially delaying product approval and impacting future revenues.
- Stock Price Decline: Following the FDA news, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 on February 2, 2026, reflecting market concerns about the company's outlook.
- Legal Implications: The investigation by Pomerantz LLP could lead to a class action lawsuit, and if fraud is confirmed, it may result in significant damages for Pharming, further affecting its financial health and market performance.
See More
Pharming Group to Present at Oppenheimer Healthcare Conference
- Conference Participation: Pharming Group will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with CEO Fabrice Chouraqui and CMO Anurag Relan presenting on February 25 at 12:40 PM ET, highlighting the company's advancements in rare disease treatments.
- Live Webcast: The presentation will be available via live webcast and replay on Pharming's website under the 'Upcoming Events' and 'News' sections, ensuring that investors and the public can access real-time information, thereby enhancing transparency.
- Investor Relations: Pharming encourages scheduling one-on-one meetings with its management team, allowing investors to connect directly through email, which strengthens investor engagement and improves the company's public image.
- Company Background: Pharming is a global biopharmaceutical company focused on developing and commercializing innovative medicines aimed at transforming the lives of patients with rare, life-threatening diseases, underscoring its strategic significance in the biopharmaceutical sector.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Pharming Group N.V. regarding potential securities fraud, focusing on whether the company and its executives engaged in unlawful business practices that could harm investors.
- FDA Response Letter: On February 1, 2026, Pharming received a Complete Response Letter from the FDA concerning its Joenja® supplemental New Drug Application, requesting additional pediatric pharmacokinetic data to ensure safety for lower weight children.
- Significant Stock Drop: Following the FDA's negative feedback, Pharming's American Depositary Receipt (ADR) fell by $3.495, or 17.07%, closing at $16.975 on February 2, 2026, indicating market concerns about the company's future prospects.
- Potential Legal Action: As the investigation unfolds, investors may face the risk of a class action lawsuit, with Pomerantz LLP providing contact information for affected investors to join potential legal proceedings for compensation.
See More
